N-formylhydroxylamines as neprilysin (NEP) inhibitors, particularly as mixed inhibitors of aminopeptidase N (APN) and neprilysin (NEP)
N-formylhydroxylamine derivatives act as mixed inhibitors of NEP and APN, addressing the limitations of current inhibitors by enhancing analgesic and antidepressant effects and providing anti-inflammatory and neuropathic pain relief without addiction or respiratory depression.
Patent Information
- Application Number
- JP2022500094
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-05
- Filing Date
- 2020-07-06
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-07-06
AI Technical Summary
Current inhibitors of zinc metalloproteases, such as neprilysin (NEP) and aminopeptidase N (APN), have limitations including addiction, physical and psychological dependence, breathing disorders, constipation, and lack peripheral anti-inflammatory and neuropathic pain benefits, necessitating the development of a compound that efficiently interacts with both enzymes to enhance analgesic and antidepressant effects without these drawbacks.
Development of N-formylhydroxylamine derivatives that act as mixed inhibitors of NEP and APN, utilizing a bidentate ligand structure to interact with zinc ions, thereby protecting enkephalins from degradation and enhancing their pharmacological activities.
The compounds provide effective analgesia and antidepressant effects without addiction or respiratory depression, while also offering anti-inflammatory and neuropathic pain relief, with synergistic interactions when combined with other antinociceptive agents.
Smart Images

Figure 0007593987000022 
Figure 0007593987000001 
Figure 0007593987000002
Abstract
Description
[Technical field]
[0001] The present invention relates to novel N-formylhydroxylamine derivatives and their use as mixed neprilysin (NEP) inhibitors, and preferably as mixed inhibitors of NEP and aminopeptidase N (APN), enzymes involved in the degradation of enkephalins, particularly in the treatment of pain. [Background technology]
[0002] Over the past few years, life science research has significantly attracted scientists to study metalloenzymes and their activity modulators (inhibitors and / or activators) in order to improve human health by selecting new therapeutic targets.
[0003] The largest category of metalloproteins consists of zinc enzymes. Over the past few years, Zn has been implicated in the physiopathology and pathogenesis of a wide variety of human disorders, ranging from infectious diseases to cancer. 2+ Substantial evidence implicating enzymes has accumulated.
[0004] Zinc 2+ Metalloproteases represent a group of important hydrolases involved in numerous physiological regulatory processes, such as respiration, arterial pressure, intestinal transit, sensation of pain and well-being, maintenance of extracellular matrix reorganization at the level of the joints, angiogenesis, protein homeostasis essential for brain activity, and control of hydration and caloric balance. These enzymes are responsible for the maturation (formation of active molecules from inactive precursors) and inactivation (formation of inactive metabolites from active molecules) of peptides and proteins. Examples include enkephalins, peptides involved in pain control, which are degraded to inactive peptides by two zinc metalloproteases, neutral aminopeptidase (APN) (Meek JL et al. (1977), Neuropharmacology, 16, 151-154) and neprilysin (NEP) (Milroy B. et al. (1978), Nature, 276, 523-526). A general feature of zinc metalloproteases is that they contain at least one Zn2+ The presence of cations is essential for the hydrolase activity of the enzyme. Thus, the conventional strategy for developing efficient inhibitors of this type of enzyme is to recognize the various binding subsites of the enzyme and to bind Zn 2+ The aim of this study is to design molecules that have groups that have a strong affinity for the agonist (review of Roques BP et al. (1993), Pharmacol Rev, 45, 87-146; Roques BP et al. (2000), TIPS, 21, 475-483).
[0005] Zinc 2+ The Zn ion is essential for the catalytic activity of these enzymes, is located at the level of the active site of the enzyme and is directly involved in the catalytic mechanism through its interaction with the substrate molecule that undergoes transformation. 2+ The change in the coordination of is likely responsible for the conformational change in the protein that induces inhibition of the enzyme's activity.
[0006] Considering the mechanism, the general structure of these zinc metalloenzyme inhibitors is Zn 2+ It is an excellent chelating agent for Zn 2+ To obtain an enzyme-inhibitor complex in which Zn is tetra- or penta-coordinated, 2+ The ligands include groups which can behave as monodentate or bidentate ligands to
[0007] Therefore, Zn 2+Compounds containing chelating groups can be considered as NEP enzyme inhibitors, and more advantageously as mixed APN and NEP enzyme inhibitors, which completely protect endogenous enkephalins from their enzymatic degradation, thereby making it possible to reveal the pharmacological activity of enkephalins, in particular their pharmacological activity as analgesics and antidepressants (Noble et al. (2007) Expert. Opin. Ther. Targets, 11, 145-149). Specific mixed inhibitors of these two enzymes already exist and are described in the literature: hydroxamic acids (FR2518088 and FR2605004), aminophosphine compounds (FR2755135, FR2777780, FR0855015), amino acid derivatives with thiol functions (FR2651229, FR0510862, FR0604030, FR0853092) and endogenous peptides (Wisner et al. (2006), PNAS, 103, 17979-17984).
[0008] These various molecules have physicochemical (solubility) and pharmacodynamic (bioavailability) properties that confer on them a pharmacological effect against different types of pain, particularly acute or chronic pain mediated by hypernociception (Noble et al. (2007), Expert. Opin. Ther. Targets, 11, 145-149) and neuropathic pain (Menendez et al. (2008), Eur J Pharmacol, 596, 50-55; Thibault et al. (2008), Eur. J. Pharmacol., 600, 71-77), either by intravenous or oral route. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] FR2518088 [Patent Document 2] FR2605004 [Patent Document 3] FR2755135
Patent Document 4
Patent Document 5
Patent Document 6
Patent Document 7
Patent Document 8
Patent Document 9
Non-Patent Document
[0010]
Non-Patent Document 1
Non-Patent Document 2
Non-Patent Document 3
Non-Patent Document 4
Non-Patent Document 5
Non-Patent Document 6
Non-Patent Document 7
Non-Patent Document 8
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
Non-licensed Document 16
Non-licensed Document 17
Non-licensed Document 18
Non-licensed Document 19
[0011] The object of the present invention is to 2+ The aim is to provide compounds that are able to efficiently chelate ions and interact with different subsites of the NEP enzyme, and also to interact in an advantageous way with the enzyme subsite of APN, and that have the beneficial properties of the substance morphine, in particular analgesia, behavioral effects (reduction of the emotional component of pain and antidepressant responses), but lack its drawbacks (addiction, physical and psychological dependence, respiratory depression, constipation). Furthermore, it would be advantageous if the compound had beneficial peripheral effects (anti-inflammatory and neuropathic pain) without the aforementioned drawbacks. [Means for solving the problem]
[0012] The present invention relates to compounds having the following general chemical formula (I): H-CO-N(OH)-CH2-CH(R1)-CO-NH-(CH2) n -CH(R2)-(CH2) m -CO-R3(I) Where: R1 represents a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, unsubstituted or substituted with one or more groups selected from the following: - aryl, which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, phenyl, benzyl, OR4, and combinations thereof, where R4 is selected from hydrogen and linear or branched alkyl groups containing from 1 to 4 carbon atoms; - 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, sulfur; - 5- or 6-membered cycloalkyl, and - 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, and sulfur; R2 stands for: - Hydrogen, - a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, unsubstituted or substituted with one or more groups selected from the following: radicals selected from OR5, SR5 and S(O)R5, where R5 is selected from hydrogen, linear or branched alkyl radicals containing 1 to 4 carbon atoms, the radical CO2R6, where R6 is selected from hydrogen, a linear or branched alkyl group containing 2 to 4 carbon atoms and the benzyl group, Aryl which is itself unsubstituted or substituted with one or more groups selected from halogen, such as fluorine or bromine, OR groups, and combinations thereof, where R has the same definition as above; 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, sulfur; 5- or 6-membered cycloalkyl, and 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, and sulfur; - aryl, unsubstituted or substituted with one or more groups selected from halogen, such as fluorine or bromine, OR5 groups, and combinations thereof, where R5 has the same definition as above; or heteroaryl containing one or more, preferably one or two heteroatoms, unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, OR groups, and combinations thereof, each heteroatom being selected from oxygen, nitrogen and sulfur, R having the same definition as defined above; R3 stands for: - R7 is an OR7 group selected from: ·hydrogen, linear or branched alkyl groups containing from 2 to 6 carbon atoms, Benzyl group, and R8 and R9 are each independently a CHR8-COOR9, CHR8-OC(=O)R9 or CHR8-OC(=O)-OR group selected from alkyl, aryl, arylalkyl, cycloalkyl, cycloheteroalkyl, heteroalkyl, heteroaryl and heteroarylalkyl groups, m and n are, independently of each other, integers selected from 0 and 1.
[0013] The compounds of formula (I) of the present invention have catalytic activity of Zn 2+ can behave like a bidentate ligand with respect to Zn 2+ It contains the N-formylhydroxylamine H-CO-N(OH)- functional group as a ligand.
[0014] The present invention also relates to a compound of formula (II): H-CO-N(OR)-CH2-CH(R1)-CO-NH-(CH2) n -CH(R2)-(CH2) m -CO-R3(II) R stands for: - a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, which is unsubstituted or substituted by one or more aryl groups, which are themselves unsubstituted or substituted by one or more groups selected from aryl or linear or branched alkyl groups containing 1 to 4 carbon atoms, or -Si(R 10 ) 3 groups, R 10 is a linear or branched alkyl group containing 1 to 4 carbon atoms. 10 )3 units, R1, R2 and R3 are as defined above; and the pharma- ceutically acceptable salts and / or solvates thereof.
[0015] The present invention also relates to compounds of formula (I) or compounds of formula (II) as described above, except that in the compounds of formula (II) the R group is a group that is labile under physiological conditions for use as a pharmaceutical, in particular as an analgesic, anxiolytic, antidepressant or anti-inflammatory agent.
[0016] The present invention also relates to pharmaceutical compositions comprising at least one compound of formula (I) or compound of formula (II) according to the invention, provided that the R group in the compound of formula (II) is a group that is labile under physiological conditions.
[0017] The present invention also relates to a pharmaceutical composition comprising at least one compound of formula (I) or of formula (II) as described above and at least one compound selected from morphine and its derivatives, inhibitors of endocannabinoids and their metabolism, GABA derivatives such as gabapentin or pregabalin, channel inhibitors such as duloxetine or Nav1.7 inhibitors, provided that the R group in the compound of formula (II) is a group that is unstable under physiological conditions.
[0018] The present invention relates to a pharmaceutical composition as described above for use as an analgesic, anxiolytic, antidepressant or anti-inflammatory agent.
[0019] Finally, the present invention relates to processes for preparing the compounds of formula (I) and the compounds of formula (II) according to the invention. [Brief description of the drawings]
[0020] [Figure 1]Figure 1 shows the effect of intravenous coadministration of compound Ib-1 with THC solubilized in (EtOH / Tween 80 / water) (1 / 1 / 8) as vehicle in the hot plate test in mice. The grey bars correspond to the analgesic response (10%) after injection of compound Ib-1 alone (at a level of 10 mg / kg). The checkered bars correspond to the analgesic response (12%) after injection of THC alone (at a level of 0.375 mg / kg). The bars containing horizontal lines correspond to the analgesic response (65%) after injection of compound Ib-1 together with compound Ib-1 (at a level of 10 mg / kg Ib-1 for 0.375 mg / kg THC). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] Within the scope of the present invention, the expression "hydrocarbon group" refers to an alkyl group, an alkenyl group or an alkynyl group as defined below. An "alkyl group" is understood within the meaning of the present invention to refer to a saturated, linear or branched hydrocarbon chain. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl groups.
[0022] An "alkenyl group" is understood within the meaning of the present invention to refer to a straight or branched hydrocarbon chain containing one or more double bonds, such as, for example, ethenyl, propenyl, butenyl, pentenyl or hexenyl groups.
[0023] An "alkynyl group" is understood within the meaning of the present invention to refer to a straight or branched hydrocarbon chain containing at least one triple bond, such as, for example, an ethynyl or propynyl group.
[0024] Within the meaning of the present invention, the hydrocarbon groups advantageously contain from 1 to 6 carbon atoms in the case of alkyl groups and from 2 to 6 carbon atoms in the case of alkenyl or alkynyl groups.
[0025] "Cycloalkyl" is taken within the meaning of the invention to denote a saturated hydrocarbon ring advantageously containing 5 or 6 carbon atoms, and in particular a cyclohexyl or cyclopentyl group.
[0026] "Cycloheteroalkyl" is understood within the meaning of the present invention to refer to a saturated hydrocarbon ring containing advantageously 5 or 6 carbon atoms, in which one or more, advantageously one to two, carbon atoms are replaced by a heteroatom selected from a sulfur atom, a nitrogen atom, an oxygen atom.
[0027] "Heteroalkyl" is understood within the meaning of the present invention to refer to an alkyl group as defined above, in which one or more, advantageously one to two, carbon atoms are replaced by a heteroatom selected from a sulfur atom, a nitrogen atom, an oxygen atom.
[0028] "Aryl" is understood within the meaning of the present invention to refer to an aromatic hydrocarbon group containing preferably from 6 to 10 carbon atoms and containing one or more condensed rings, which is advantageously a phenyl or naphthyl group, preferably a phenyl group.
[0029] "Arylalkyl" is understood within the meaning of the present invention to mean an alkyl group as defined above, in which one or more, preferably one or two, hydrogen atoms, carried by the same carbon atom or by several different carbon atoms, are replaced by an aryl group as defined above, which is advantageously a benzyl group.
[0030] "Heteroaryl" is understood within the meaning of the present invention to refer to an aromatic group, advantageously containing 5 or 6 atoms, in which one or more, advantageously 1 to 2, carbon atoms are replaced by heteroatoms selected from sulfur, nitrogen, oxygen. Examples of heteroaryl groups are furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolyl, quinoxalyl or indolyl. Preference is given to the thienyl group, which is an isostere of the phenyl group.
[0031] "Heteroarylalkyl" is understood within the meaning of the present invention to refer to an alkyl group as defined above, in which one or more, preferably one or two, hydrogen atoms carried by the same carbon atom or by several different carbon atoms are replaced by a heteroaryl group as defined above.
[0032] The term "halogen" refers to chlorine, bromine, iodine, fluorine. Advantageously, it is a fluorine, bromine or chlorine atom. Even more advantageously, it is a fluorine or bromine atom, preferably a fluorine atom.
[0033] "Unsaturated" is understood within the meaning of the present invention to indicate that the hydrocarbon chain may contain one or more unsaturations, advantageously one.
[0034] "Unsaturated" is understood within the meaning of the present invention to refer to double or triple carbon-carbon bonds (C=C or C≡C).
[0035] "Stereoisomers" is taken within the meaning of the present invention to refer to geometrical or optical isomers.
[0036] Geometric isomers arise from different arrangements of substituents on a double bond and can result in a Z or E configuration.
[0037] Optical isomers are the result of alternative arrangements in space of the substituents, particularly at a carbon atom that contains four different substituents. This carbon atom then constitutes a chiral or asymmetric center. Optical isomers are made up of diastereoisomers and enantiomers. Optical isomers that are mirror images of each other but are not superimposable are referred to as "enantiomers". Optical isomers that are neither superimposable nor mirror images are referred to as "diastereoisomers".
[0038] A mixture containing equal amounts of two individual enantiomeric forms of opposite chirality is referred to as a "racemic mixture."
[0039] A "chiral group" is understood within the meaning of the present invention to refer to a group that is not superimposable on its mirror image. Such chiral groups in particular contain an asymmetric carbon atom, i.e. a carbon atom substituted with four different substituents (containing hydrogen).
[0040] "Absolute configuration" is understood within the meaning of the present invention to refer to the spatial arrangement of atoms or chemical groups around an asymmetric carbon atom to which the atom or chemical group is attached. The two possible absolute configurations of the asymmetric carbon are designated S and R.
[0041] "Enantioselective synthesis" is understood within the meaning of the present invention to refer to a synthesis leading to a single enantiomer of the resulting synthetic molecule.
[0042] The term "N-formylation reaction" refers to a reaction during which a nitrogen atom of an organic compound is replaced by a formyl-CHO group.
[0043] The term "peptide coupling agent" refers to an organic reagent capable of activating a carboxylic acid functional group of an organic compound so that the carboxylic acid functional group can form a peptide bond with the terminal amine functional group of another organic compound. The most commonly used coupling agents include HATU (dimethylamino)-N,N-dimethyl(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)methaniminium hexafluorophosphate), TBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate), BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate), PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), HOBt (hydroxybenzotriazole), or carbodiimides such as DCC (dicyclohexylcarbodiimide) and EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide). Such coupling agents may also be used in combination with others. For example, EDC is often used in combination with HOBt in peptide coupling reactions.
[0044] "Physiologically labile groups" are understood within the meaning of the present invention to refer to common protecting groups for chemical groups, such as hydroxyl, amine or acid functional groups, which are removed under physiological conditions when they penetrate the body. For example, upon oral administration, the acidic pH of the stomach will cause deprotection of the labile groups.
[0045] The compound of the present invention may be in the form of its pharma- ceutically acceptable salt or solvate. In the present invention, "pharma-ceutically acceptable" is generally understood to mean safe, non-toxic, acceptable for veterinary use and human medicine, and useful for preparing pharmaceutical compositions.
[0046] A "pharmaceutically acceptable salt" of a compound is intended to refer to a salt that is pharmaceutically acceptable, as defined herein, and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) Pharmacologically acceptable addition salts formed with bases, and (2) Hydrates and solvates thereof.
[0047] Usually, the compounds of formula (I) are in the form of addition salts obtained with pharmacologically acceptable organic or inorganic bases or metal ions, such as alkali metal ions or alkaline earth metal ions. Organic bases are, for example, diethanolamine, ethanolamine, N-methylglucamine, triethanolamine and tromethamine. Inorganic bases are, for example, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide. Solvates acceptable for therapeutic use of the compounds of the present invention include conventional solvates, such as those formed during the final stage of preparation of the compounds, due to the potential presence of solvents. For example, solvates may be due to the presence of water (called hydrates) or ethanol. The solvates are preferably alcoholates, such as ethanolates.
[0048] Preferably, the compounds of the present invention are in the form of their sodium salts or hydrates.
[0049] R1 advantageously represents a linear or branched hydrocarbon group containing from 1 to 6 carbon atoms substituted with one or more groups chosen from: - aryl, which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, phenyl, benzyl, OR4, and combinations thereof, where R4 is selected from hydrogen and linear or branched alkyl groups containing from 1 to 4 carbon atoms; - 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, sulfur; - 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, and sulfur;
[0050] R1 advantageously represents a linear or branched hydrocarbon group containing from 1 to 6 carbon atoms, unsubstituted or substituted with an aryl which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, phenyl groups, benzyl groups, OR4 groups, and combinations thereof, and R4 is selected from hydrogen and linear or branched alkyl groups containing from 1 to 4 carbon atoms.
[0051] According to a preferred embodiment, R1 represents a linear or branched hydrocarbon group containing from 1 to 6 carbon atoms, which is itself unsubstituted or substituted with aryl, which is substituted with one or more groups selected from halogens such as fluorine and bromine, phenyl groups, benzyl groups, OR4 groups, and combinations thereof, and R4 is selected from hydrogen and linear or branched alkyl groups containing from 1 to 4 carbon atoms.
[0052] More advantageously, R1 represents an aryl, itself unsubstituted or substituted by a phenyl group, preferably a hydrocarbon group substituted by a phenyl group, preferably a linear or branched alkyl group containing from 1 to 6, preferably 1, carbon atoms.
[0053] According to a particular embodiment, the carbon bearing R1 has the absolute configuration (R) or (S), preferably (R).
[0054] R2 advantageously represents: - Hydrogen, or - a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, which is unsubstituted or substituted with one or more groups selected from the following: radicals selected from OR5, SR5 and S(O)R5, where R5 is selected from hydrogen, linear or branched alkyl radicals containing 1 to 4 carbon atoms, the radical CO2R6, where R6 is selected from hydrogen, a linear or branched alkyl group containing 2 to 4 carbon atoms and the benzyl group, Aryl which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, OR groups, and combinations thereof, where R has the same definition as above. 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, sulfur; 5- or 6-membered cycloalkyl, and 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen and sulfur.
[0055] According to another embodiment, R2 advantageously represents: - a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, which is unsubstituted or substituted with one or more groups selected from the following: radicals selected from OR5, SR5 and S(O)R5, where R5 is selected from hydrogen, linear or branched alkyl radicals containing 1 to 4 carbon atoms, the radical CO2R6, where R6 is selected from hydrogen, a linear or branched alkyl group containing 2 to 4 carbon atoms and the benzyl group, Aryl which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, OR groups, and combinations thereof, where R has the same definition as above. 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, sulfur; 5- or 6-membered cycloalkyl, and 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, and sulfur; - aryl, unsubstituted or substituted with one or more groups selected from halogen, such as fluorine or bromine, OR5 groups, and combinations thereof, where R5 has the same definition as above; or - heteroaryl containing one or more, preferably one or two heteroatoms, unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, OR groups, and combinations thereof, where R has the same definition as above and each heteroatom is selected from oxygen, nitrogen and sulfur.
[0056] According to a preferred embodiment, R2 represents a linear or branched hydrocarbon group containing from 1 to 6 carbon atoms, unsubstituted or substituted with one or more groups selected from the following: radicals selected from OR5, SR5 and S(O)R5, where R5 is selected from hydrogen, linear or branched alkyl radicals containing 1 to 4 carbon atoms, the radical CO2R6, where R6 is selected from hydrogen, a linear or branched alkyl group containing 2 to 4 carbon atoms and the benzyl group, Aryl which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, OR groups, and combinations thereof, where R has the same definition as above. 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, sulfur; 5- or 6-membered cycloalkyl, and 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen and sulfur.
[0057] More advantageously, R2 represents a linear or branched hydrocarbon group, preferably an alkyl group, containing from 1 to 6 carbon atoms, unsubstituted or substituted with one or more groups selected from the following: Aryl which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, OR groups, and combinations thereof, where R has the same definition as above. 5- or 6-membered cycloalkyl, and 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen and sulfur.
[0058] In particular, R2 represents a linear or branched hydrocarbon group, preferably an alkyl group, containing 1 to 6 carbon atoms, unsubstituted or substituted with aryl, which is itself unsubstituted or substituted with one or more groups selected from halogens such as fluorine and bromine, OR5 groups, and combinations thereof, and R5 has the same definition as above. More specifically, the group R2 represents a linear or branched hydrocarbon group, preferably an alkyl group, containing 1 to 6 carbon atoms, unsubstituted or substituted with aryl, which is itself unsubstituted. Preferably, the aryl group is a phenyl group. Even more advantageously, the group R2 represents a linear or branched alkyl group, containing 1 to 6, preferably 1, carbon atoms, unsubstituted or substituted with phenyl, which is itself unsubstituted.
[0059] According to a particular embodiment, the carbon bearing R2 has the absolute configuration (R) or (S), preferably (S).
[0060] R3 advantageously represents an OR7 group, with R7 chosen from: ·hydrogen, linear or branched alkyl groups containing from 2 to 6 carbon atoms, and Benzyl group.
[0061] According to a preferred embodiment, R3 represents an OR7 group, R7 being selected from: Hydrogen, and · Straight or branched alkyl groups containing from 2 to 6 carbon atoms.
[0062] In an even more preferred manner, R3 represents an OH group.
[0063] According to a particular embodiment, within the scope of formula (I): R1 represents a linear or branched hydrocarbon group, especially an alkyl group, containing 1 to 6 carbon atoms, which is itself unsubstituted or substituted with one or more groups selected from fluorine, bromine, a phenyl group, a benzyl group, an OR4 group, and combinations thereof, preferably with a phenyl group, and R4 is selected from hydrogen and a linear or branched alkyl group containing 1 to 4 carbon atoms; R2 represents a linear or branched hydrocarbon group, preferably an alkyl group, containing 1 to 6 carbon atoms, which is unsubstituted or substituted with one or more groups selected from the following: Aryl which is itself unsubstituted or substituted with one or more groups selected from fluorine, bromine, OR5 groups, and combinations thereof, where R5 is selected from hydrogen, linear or branched alkyl groups containing 1 to 4 carbon atoms. 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, sulfur; 5- or 6-membered cycloalkyl, and 5- or 6-membered cycloheteroalkyl containing 1 or 2 heteroatoms, each heteroatom being selected from oxygen, nitrogen, and sulfur; Preferably, R2 represents a linear or branched alkyl group containing from 1 to 6 carbon atoms, which is unsubstituted or substituted with phenyl. R3 represents an OR7 group, and R7 is selected from the following: Hydrogen, and linear or branched alkyl groups containing from 2 to 6 carbon atoms, Preferably, R7 is hydrogen.
[0064] According to a particular embodiment, the compound of formula (I) according to the invention is the following compound: - R1= (R)-CH2Ph; R2= (S)-CH3; R3= OH; n=m=0; - R1= (S)-CH2Ph; R2= (S)-CH3; R3= OH; n=m=0; - R1= (R)-CH2Ph; R2= (S)-CH2Ph; R3= OH; n=m=0; - R1= (S)-CH2Ph; R2= (S)-CH2Ph; R3= OH; n=m=0; - R1= (R)-CH2Ph; R2= (S)-CH2Ph; R3= OH; n=0; m=1; - R1= (S)-CH2Ph; R2= (S)-CH2Ph; R3= OH; n=0; m=1; - R1= (R)-CH2Ph-4-Ph; R2= (S)-CH3; R3= OH; n=m=0; - R1= (S)-CH2Ph-4-Ph; R2= (S)-CH3; R3= OH; n=m=0; R1=(S)-CH2Ph; R2=(S)-CH2Ph; R3=OH; n=1; m=0; or - Any of the compounds where R1= (R)-CH2Ph; R2= (S)-CH2Ph; R3= OH; n=1; m=0 or a pharma- ceutically acceptable salt and / or solvate thereof.
[0065] In a preferred method, the compound of the invention comprises - R1= (R)-CH2Ph; R2= (S)-CH3; R3= OH; n=m=0; - R1= (R)-CH2Ph; R2= (S)-CH2Ph; R3= OH; n=m=0; - R1= (R)-CH2Ph; R2= (S)-CH2Ph; R3= OH; n=0; m=1; R1=(R)-CH2Ph-4-Ph; R2=(S)-CH3; R3=OH; n=m=0; or - R1 = (R)-CH2Ph; R2 = (S)-CH2Ph; R3 = OH; n = 1; m = 0.
[0066] The present invention also relates to a compound of formula (II): H-CO-N(OR)-CH2-CH(R1)-CO-NH-(CH2) n -CH(R2)-(CH2) m -CO-R3(II) where: R stands for: - a linear or branched hydrocarbon group containing 1 to 6 carbon atoms which is unsubstituted or substituted by one or more aryl groups, which are themselves unsubstituted or substituted by one or more groups selected from aryl or linear or branched aryl groups containing 1 to 4 carbons, or -Si(R 10 ) 3 groups, R 10 is a linear or branched alkyl group containing 1 to 4 carbon atoms. 10 ) 3 units, and R1, R2, R3, m and n are as defined above.
[0067] Preferably, R represents a linear or branched alkyl group containing 1 to 6 carbon atoms and unsubstituted or substituted with an aryl group, preferably phenyl, or R represents Si(R 10 ) 3 groups, R 10 is preferably methyl. In a more preferred manner, R represents a benzyl group.
[0068] When R is a labile chemical group as described above, compound (II) is converted to compound (I) when it penetrates the body under the action of physiological conditions suitable for deprotection of the R group, so that compound (II) constitutes a prodrug of compound (I).
[0069] The compounds of the present invention of formula (I) or formula (II) can be used as medicines if the R group is an unstable group under physiological conditions. More specifically, these compounds can be used in combination with at least one pharma- ceutically acceptable excipient to prepare pharmaceutical compositions containing at least one of the compounds as active ingredients. The excipient can be selected according to the desired dosage form and mode of administration from among the usual excipients known to those skilled in the art.
[0070] The compounds of the present invention jointly inhibit the enzymatic activity involved in the degradation of enkephalins and increase their extracellular endogenous levels, and in this respect have been found to be efficient analgesics and / or antidepressants.The analgesic effect of the compounds is manifested in various types of acute or chronic pain, such as postoperative pain, cancer pain, traumatic pain, headache, migraine, visceral pain, neurogenic pain, neuropathic pain, neuroinflammatory pain, nociceptive pain or general pain, such as fibromyalgia. Examples of pain include mechanical pain (e.g., muscle pain, vascular ischemia), pain caused by shingles, cancer pain related to the cancer itself or the results of its treatment, pain related to anti-inflammatory or degenerative diseases (e.g., arthritis, rheumatoid arthritis, osteoarthritis, gout), pain related to type 1 and type 2 diabetes, pain related to migraine, facial neuralgia, headache, pain related to peripheral nerve disorders, dorsal lumbar neuralgia, cervical brachial, dental pain, pain related to burns, sunburn, bites or stings, pain related to infections, metabolic disorders (diabetes, alcoholism), nerve compression (herniated disc, carpal tunnel, fibrosis, etc.), fractures, burns, hematomas, cuts and inflammation, visceral pain (intestine, caused by anti-inflammatory diseases of the intestine and functional bowel disorders, urinary cholecystitis such as renal colic, genitals such as cystitis, dysmenorrhea, cystitis, cardiac endometriosis such as pain from a cardiac myocardial infarction.
[0071] Finally, typically and advantageously, the compounds of the invention do not suffer from the major drawbacks of morphine-based substances (tolerance, physical dependence, respiratory depression, nausea, sedation, constipation, etc.).
[0072] Thus, the compounds of the present invention of formula (I) or formula (II), wherein the R group is a group that is labile under physiological conditions, and the pharmaceutical composition comprising same, may be useful for at least one application selected from analgesics, anxiolytics, antidepressants or anti-inflammatory agents.
[0073] The present invention also relates to the use of compounds of formula (I) or formula (II) as defined above, provided that the group R is a group that is unstable under physiological conditions, and pharmaceutical compositions containing them, for the manufacture of a medicament intended for the treatment of analgesics, anxiolytics, antidepressants or anti-inflammatory agents, more particularly pain, which may in particular be chronic or acute pain as defined above.
[0074] The present invention also relates to a method for treating pain, in particular chronic or acute pain as defined above, which method comprises administering to a patient in need thereof, preferably by parenteral, oral or nasal route, an effective amount of a compound of formula (I) or formula (II) according to the invention or a pharma- ceutically acceptable salt and / or solvate thereof, or a composition of the invention, if the R group is a group that is labile under physiological conditions.
[0075] In the present invention, the patient (suffering from pain as defined above, in particular chronic or acute pain) is usually an animal, preferably a mammal, advantageously a human being.
[0076] The compounds of the present invention may be used alone or in combination with compounds known for their antinociceptive properties, which may allow for an interaction of pharmacological effects, especially since known antinociceptive compounds generally have undesirable secondary effects at strong doses.
[0077] Such synergy of pharmacological effects has been demonstrated in the past by combining mixed inhibitors with chemical structures different from those of the present invention with compounds that are known antinociceptive agents. Thus, potent interactions of antinociceptive responses have been obtained, for example, in combination with morphine (Mas Nieto et al. (2001), Neuropharmacol. 41, 496-506), THC (Valverde et al. (2001), Eur. J. Neurosci., 13, 1816-1824), gabapentin (Menendez et al. (2007), Eur. J. Pharmacol., 596, 50-55) and analogs such as pregabalin. These associations allow the doses of the associated components (e.g., morphine and inhibitors) to be reduced by 3-10 times for comparable pharmacological effects.
[0078] Thus, according to one embodiment, the pharmaceutical composition comprises at least one of the compounds of the invention as active ingredients in combination with at least one antinociceptive agent and at least one pharma- ceutically acceptable excipient. The antinociceptive agent may be selected from: - morphine and its derivatives, - Endocannabinoids and their metabolic inhibitors, Δ 9 THC, synthetic cannabinoid receptor agonists or anandamide breakdown inhibitors (FAAH), - GABA derivatives such as gabapentin and pregabalin, - Duloxetine, a serotonin or noradrenaline reuptake inhibitor or - Channel inhibitors such as Nav1.7 inhibitors.
[0079] According to one embodiment, the pharmaceutical composition of the present invention comprises at least one compound of the present invention as an active ingredient in combination with THC. a) a first composition comprising at least one compound of formula (I) or formula (II) as defined above, where R is a group that is labile under physiological conditions; and b) a second composition comprising at least one other active ingredient, in particular an analgesic, selected from morphine and its derivatives, endocannabinoids and their metabolic inhibitors, GABA derivatives such as gabapentin or pregabalin, channel inhibitors such as duloxetine or Nav1.7 inhibitors, and wherein the kit is a combination product for simultaneous, separate or over time use.
[0080] The kit according to the invention is especially useful as an analgesic, anxiolytic, antidepressant or anti-inflammatory agent, in particular for the treatment of pain, typically chronic or acute pain as defined above.
[0081] The pharmaceutical compositions according to the invention can be administered by parenteral route, such as intravenous or intradermal route, or by topical, oral or nasal route.
[0082] Forms that can be administered by parenteral route include aqueous suspensions, isotonic saline solutions, or sterile injectable solutions, which may contain dispersants and / or pharmacologically compatible wetting agents. Forms that can be administered by oral route include tablets, soft or hard capsules, powders, pills, oral solutions and suspensions. Forms that can be administered by nasal route include aerosols. Forms that can be administered by topical route include patches, gels, creams, ointments, lotions, sprays, and eye drops.
[0083] The effective amount of the compounds of the invention will vary as a function of many parameters, such as, for example, the selected route of administration, the weight, age, sex, the state of the disease being treated, and the susceptibility of the individual being treated.
[0084] The present invention also relates to a process for preparing the compounds of formula (I) and of formula (II) according to the invention, said process comprising the following successive steps: (a) a chemical formula (III): H-CO-N(OR)-CH2-CH(R1)-C(O)OH(III) and a compound of the following formula (IV): H3N + -(CH2) n -CH(R2)-(CH2) m -C(O)R3(IV) in the presence of a peptide coupling agent such as TBTU, HATU, EDC, HOBt, BOP, PyBOP, DCC or combinations thereof, wherein R, R1, R2, R3, n and m are as defined above, resulting in the formation of a compound of formula (II) as defined above, (b) deprotection of the compound of formula (II) resulting from step (a), resulting in derivation of a compound of formula (I).
[0085] The compounds of formula (I) potentially have one to three asymmetric centers. The groups R1, R2 and R3 are usually introduced to obtain an optically pure configuration corresponding to the stereochemistry observed for interaction with the active site of the enzyme concerned.
[0086] Process (a): According to a particular embodiment, the compound of formula II can be obtained by the following synthetic steps: (i-1) Reaction of acrylic acid derivative V with hydroxylamine VI to give acid VII,
[0087] [ka]
[0088] where R and R1 are as previously defined.
[0089] Preferably, the hydroxylamine VI corresponds to benzylhydroxylamine.
[0090] (i-2) N-formylation reaction of acid VII in formic acid in the presence of acetic anhydride gives the compound of formula III.
[0091] [ka]
[0092] Compound III then undergoes peptide coupling with a compound of formula IV to give a compound of formula II:
[0093] [ka]
[0094] where R, R1, R2, R3, n and m are as defined above.
[0095] Preferably, the coupling agent used is TBTU. Advantageously, the reaction is carried out in an aprotic polar solvent such as DMF, in the presence of DIEA (diisopropylethylamine).
[0096] According to a preferred embodiment, compound IV is enantiomerically pure. The carbon bearing the R2 group has a resolved absolute configuration, advantageously corresponding to the absolute configuration (S).
[0097] According to another method, a method for preparing a compound of formula I comprises the steps of: (a') combining a compound of formula III with a compound of formula VIII: H3N + -(CH2) n -CH(R2)-(CH2) m -C(O)OP(VIII) where R2 is as defined above and OP is a precursor of R3, P may for example be identical to R, in particular P may be a benzyl group, resulting in a compound of formula IX: H-CO-N(OR)-CH2-CH(R1)-CO-NH-(CH2) n -CH(R2)-(CH2) m -C(O)-OP(IX) This leads to the formation of where R, R1, R2, P, n, and m are as defined above. (b') conversion of the OP group of compound IX to a R3 group as defined above, resulting in a compound of formula II or formula I as defined above.
[0098] (c') optionally deprotecting the compound of formula II resulting from step (b') to give a compound of formula I.
[0099] Step (b') of conversion of the R3 group to the R3 group of the OP group precursor is carried out according to methods well known to those skilled in the art, which include, for example, deprotection, oxidation or reduction steps.
[0100] In the case where P is identical to R, the deprotection of the P group also results in the deprotection of the amine bearing the R group, and the compound of formula I is obtained directly at the end of step (b'). In this case, step (c') is not necessary. This situation occurs especially when R3 is equal to OH, and especially when P and R are both benzyl and are removed, for example, by a hydrogenation reaction.
[0101] Process (b): Step (b) corresponds to the deprotection of the amine bearing an OR group to give a compound of formula I, wherein said amine bears an OH group.
[0102] [ka]
[0103] Compound I is obtained in the form of at least two diastereoisomers. The diastereoisomers can be obtained in diastereoisomeric pure form by methods well known to those skilled in the art, usually by preparative or semi-preparative HPLC, where the carbons carrying R1, R2 and optionally R8 or R9 (according to the definition of R3) are separated and are in their respective absolute configurations that optimize the properties of the compounds of the present invention. In particular, the carbon carrying R1 is in absolute configuration (R) or (S), preferably (R), and the carbon carrying R2 is in absolute configuration (S). When present, the carbon carrying R8 or R9 is in absolute configuration (R) or (S).
[0104] Thus, in a preferential manner, the compounds of formula I can correspond to two diastereoisomers:
[0105] [ka]
[0106] and
[0107] [ka]
[0108] Here, R3 preferably represents OH.
[0109] Enantioselective synthesis Compounds of formula (II) can also be enantioselectively synthesized by the methodology of Oppolzer's auxiliary (Heravi M & Zadsirjan V (2014), Tetrahedron: Asymmetry, 1061-1090) according to the following steps:
[0110] 1° The acrylic acid derivative V reacts with thionyl chloride SOCl2 to give the acid chloride X:
[0111] [ka]
[0112] 2° Acid chloride X is then coupled to Oppolzer's auxiliary ((1R)-(+)-2,10-camphorsultam) in the presence of a strong base to give compound XI:
[0113] [ka]
[0114] 3° Stereoselective Michael addition of hydroxylamines VI to compounds XI allows the access to compounds XII in an optically pure manner:
[0115] [ka]
[0116] The 4° chiral auxiliary is cleaved by strong base to give optically pure compound XIII-1 (Naeslund C et al. (2005), Tetrahedron, 61, 1181-1186):
[0117] [ka]
[0118] 5° The synthetic steps leading to compounds III-1 and II-1 are the same as those used for the synthesis of the racemic products described previously. EXAMPLES
[0119] The present invention is further illustrated by the following examples, without being limited in any way.
[0120] List of abbreviations: Ac2O: acetic anhydride AcOEt: ethyl acetate Bn: Benzyl DIEA: Diisopropylethylamine DMF: Dimethylformamide DMSO: Dimethyl sulfoxide HPLC: High-performance liquid chromatography Ph: Phenyl Yd: Yield NMR: nuclear magnetic resonance Rt: retention time TFA: Trifluoroacetic acid
[0121] Synthesis of Compounds of the Invention The acrylic acid V is commercially available or alternatively is synthesized as described in Organic Syntheses, (1955) coll. Vol. 3, p. 377; (1945) vol. 25, p. 42.
[0122] The absolute configuration of the carbon bearing R1 was determined after separation of the two diastereoisomers Ia and analysis by NMR of the protons of the chemical substitution of the CH3 group, according to the rules established by Fournie-Zaluski et al. in J Med Chem (1986), 29, 751-753.
[0123] Thus, the absolute configuration ascribed to compound Ia-1 is (2R,3S), and that of compound Ia-2 is (2S,3S). The absolute configurations of the analogs were fixed by the similarity of the stereochemistry of the correct diastereoisomer with the highest enzyme affinity.
[0124] Step 1: Synthesis of 2-alkyl-3-(benzylamino)propanoic acids VIIa where R=Bn
[0125] [ka]
[0126] Benzylhydroxylamine VIa (4 eq.) is reacted with acrylic acid V at 50° C. for 8 h. The mixture is poured into AcOEt. Excess benzylhydroxylamine is removed by washing with 1N HCl. The organic phase is washed with a saturated solution of NaCl, dried over Na2SO4 and concentrated under reduced pressure. The oil is triturated with ether to give the solid compound VIIa.
[0127] VIIa-1 2-Benzyl-3-(benzyloxyamino)propanoic acid R1= CH2Ph: solid, (Yd: 80.9%) NMR (DMSO + TFA, 400 MHz): 2.7-3.3 (4H, m); 3.51 (1H, q); 4.95 (2H, s); 7.1-7.4 (10H, m) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 6 / 4 Rt= 7.3 min
[0128] VIIa-2 3-(benzyloxyamino)-2-(biphenyl-4-ylmethyl)propanoic acid R1= CH2Ph(4-Ph): solid, (Yd: 87.7%) NMR (DMSO + TFA, 400 MHz): 2.8-3.1 (3H, m); 3.25-3.35 (1H, q); 3.55 (1H, q); 4.95 (2H, s); 7.1-7.6 (14H, m) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 7 / 3 Rt= 8.7 min
[0129] Step 2: Synthesis of 2-alkyl-3-(N-(benzyloxy)formamido)propanoic acids (IIIa, R = Bn)
[0130] [ka]
[0131] Acid VIIa is solubilized in formic acid at 0° C. Acetic anhydride is added at 0° C. and the mixture is stirred for 3 h at 0° C. After pouring the mixture into ether, the mixture is evaporated to dryness to give acid IIIa, which is used directly in the next step.
[0132] IIIa-1 2-benzyl-3-(N-(benzyloxy)formamido)propanoic acid R1= CH2Ph: Oil, (Yd: 100%) NMR (DMSO + TFA, 400 MHz): 2.6-3.0 (4H, m); 3.51 (1H, q); 4.80 (2H, s); 7.1-7.4 (10H, m); 7.85 (0.5H, s), 8.15 (0.5H, s) (CHO) cis / trans HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 6 / 4 Rt= 7.2 min
[0133] IIIa-2 3-(N-(benzyloxy)formamido)-2-(biphenyl-4-ylmethyl)propanoic acid R1= CH2Ph(4-Ph): Oil, (Yd: 100%) NMR (DMSO + TFA, 400 MHz): 2.8-3.1 (3H, m); 3.25-3.35 (1H, q); 3.55 (1H, q); 4.95 (2H, s); 7.1-7.6 (14H, m); 7.85 (0.5H, s), 8.15 (0.5H, s) (CHO) cis / trans HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 7 / 3 Rt= 8.7 min
[0134] Step 3: Amino acid coupling, synthesis of compound IIa
[0135] [ka]
[0136] The acid IIIa and the amino acid salt, benzyl ester (1.2 eq.) IV are solubilized in DMF at 0° C. TBTU (1.2 eq.) and DIEA (3 eq.) are added and the mixture is stirred at ambient temperature for 15 min. DMF is evaporated under reduced pressure and the mixture is taken up in AcOEt. The organic phase is washed with a 10% aqueous solution of citric acid, a saturated solution and dried over Na2SO4.
[0137] The crude mixture is purified by semi-preparative HPLC on a Kromasil C18 column 21.2×250 mm using CH3CN / H2O (0.05% TFA) 65 / 35 as the elution system to give compound IIa.
[0138] IIa-1 (2S)-Benzyl 2-(2-benzyl-3-(N-(benzyloxy)formamido)propanamido)propanoic acid R1= CH2Ph, R2= (S)-CH3, n=m=0: Solid, (Yd: 58.2%) NMR (DMSO + TFA, 400 MHz): 1.0-1.3 (3H, m); 2.5-3.1 (3H, m); 3.15-3.60 (1H, m), 3.60 (1H, qt); 4.25 (1H, q); 4.6-4.85 (2H, m); 515 (2H, s); 7.0-7.4 (10H, m); 7.7-8.15 (1H, m); 8.3-8.6 (1H, m) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 7 / 3, Rt = 151 and 16.6 min ESI (+): [M + Na] + = 497.35; [(M-CH2Ph) + Na] + = 406.24
[0139] IIa-2 (2S)-Benzyl 2-(2-benzyl-3-(N-(benzyloxy)formamido)propanamido)-3-phenylpropanoic acid R1= CH2Ph, R2= (S)-CH2Ph, n=m=0: solid, (Yd: 64.5%) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 6 / 4, Rt = 16.9 and 17.9 min ESI (+): [M + Na] + = 573.25; [(M-CH2Ph) + Na] + = 482.14
[0140] IIa-3 (3S)-Phenyl 3-(2-benzyl-3-(N-(benzyloxy)formamido)propanamido)-4-phenylbutanoic acid R1= CH2Ph, R2= (S)-CH2Ph, n=0; m=1: solid, (Yd: 66.5%) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 6 / 4, Rt = 15.2 and 16.1 min ESI (+): [M + Na] + = 587.26; [(M-CH2Ph) + Na] + = 496.14
[0141] IIa-4 (2S)-Benzyl 2-(3-(N-(benzyloxy)formamido)-2-(biphenyl-4-ylmethyl)propanamido)propanoic acid R1= CH2Ph(4-Ph), R2= (S)-CH3, n=m=0:Solid, (Yd: 59.2%) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 7 / 3, Rt = 16.2 and 17.2 min ESI (+): [M + Na] + = 497.26; [(M-CH2Ph) + Na] + = 406.14
[0142] IIa-5 (2S)-Phenyl 2-benzyl-3-(2-benzyl-3-(N-(benzyloxy)formamido)propanamido)propanoic acid R1 = CH2Ph, R2 = (S)-CH2Ph, n = 1, m = 0: colorless oil, (Yd: 31.0%) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 7 / 3, Rt = 10.6 and 11.3 min ESI (+): [M + Na] + = 587.26; [(M-CH2Ph) + Na] += 496.14
[0143] (S)-Alanine benzyl ester (R2 = (S)-CH3, n = m = 0) and (S)-phenylalanine benzyl ester (R2 = (S)-CH2Ph, n = m = 0) are commercially available.
[0144] (S)-beta-homophenylalanine benzyl ester (R2 = (S)-CH2Ph, n = 0, m = 1), (R)-beta-2-homophenylalanine benzyl ester (R2 = (S)-CH2Ph, n = 1, m = 0) are prepared from commercially available Boc(S)-beta-homophenylalanine and Boc(R)-beta-2-homophenylalanine, respectively, by esterification to the benzyl ester and deprotection of the Boc, as described in the literature and known to those skilled in the art (Hassner A and Alexanian V (1978), Tetrahedron Lett, 19, 4475; Ripka AS et al. (1998), Bioorg Med Chem Lett, 8, 357).
[0145] Step 4: Deprotection of Compound IIa and Separation of Diastereoisomer I with R3=OH
[0146] [ka]
[0147] Compound IIa is solubilized in MeOH. Pd / C is added and the mixture is left under an atmosphere of hydrogen at room temperature for 2 h. Conversion is followed by HPLC. Pd / C is filtered through Celite. The solvent is evaporated under reduced pressure to give a mixture which is purified and separated into the two diastereoisomers I by semi-preparative HPLC on a Kromasil C18 column 21.2 x 250 mm using CH3CN / H2O (0.05% TFA) 35 / 65 as the eluent system.
[0148] Ia-1 (S)-2-((R)-2-benzyl-3-(N-hydroxyformamido)propanamido)propanoic acid R1= (R)-CH2Ph, R2= (S)-CH3, n=m=0: solid, (Yd: 31.6 %) NMR (DMSO + TFA, 400 MHz): 1.15 (3H, t); 2.5-3.2 (4H, m); 3.35-3.70 (1H, m); 4.15 (1H, t); 7.1-7.3 (5H, m); 7.7-8.15 (1H, m) and 8.1-8.3 (1H, m) (CHO, cis / trans isomers). HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 3 / 7, Rt= 6.2 min
[0149] Ia-2 (S)-2-((S)-2-benzyl-3-(N-hydroxyformamido)propanamido)propanoic acid R1= (S)-CH2Ph, R2= (S)-CH3, n=m=0: Solid, (Yd: 23.4 %) NMR (DMSO + TFA, 400 MHz): 1.0 (3H, t); 2.5-2.75 (2H, m); 2.95 (1H, m); 3.35-3.70 (2H, m); 4.05 (1H, qt); 7.1-7.3 (5H, m); 7.8-8.25 (1H, m) and 8.05-8.2 (1H, m) (CHO, cis / trans isomers). HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 3 / 7, Rt= 8.5 min
[0150] Ib-1 (S)-2-((R)-2-benzyl-3-(N-hydroxyformamido)propanamido)-3-phenylpropanoic acid R1= (R)-CH2Ph, R2= (S)-CH2Ph, n=m=0: Solid, (Yd: 23.0 %) NMR (DMSO + TFA, 400 MHz): 2.6-3.1 (5H, m); 3.15-3.40 (2H, m), 3.55 (1H, q); 4.40 (1H, m); 6.9-7.3 (10H, m); 7.7-8.15 (1H, m) and 8.20-8.35 (1H, m) (CHO, cis / trans isomers). HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 35 / 65, Rt= 12.2 min
[0151] Ib-2 (S)-2-((S)-2-benzyl-3-(N-hydroxyformamido)propanamido)-3-phenylpropanoic acid R1= (S)-CH2Ph, R2= (S)-CH2Ph, n=m=0: Solid, (Yd: 29.0 %) NMR (DMSO + TFA, 400 MHz): 2.6-3.1 (5H, m); 3.15-3.40 (2H, m), 3.55 (1H, q); 4.40 (1H, m); 6.9-7.3 (10H, m); 7.7-8.15 (1H, m) and 8.10-8.35 (1H, m) (CHO, cis / trans isomers). HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 35 / 65, Rt= 20.5 min
[0152] Ic-1 (S)-3-((R)-2-benzyl-3-(N-hydroxyformamido)propanamido)-4-phenylbutanoic acid R1= (R)-CH2Ph, R2= (S)-CH2Ph, n=0, m=1: Solid, (Yd: 35.0 %) NMR (DMSO + TFA, 400 MHz): 2.15-2.85 (7H, m); 3.15-3.40 (2H, m); 4.25 (1H, m); 6.9-7.3 (10H, m); 7.6-8.3 (2H, m) (CHO, cis / trans isomers) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 35 / 65, Rt= 9.95 min
[0153] Ic-2 (S)-3-((R)-2-benzyl-3-(N-hydroxyformamido)propanamido)-4-phenylbutanoic acid R1= (S)-CH2Ph, R2= (S)-CH2Ph, n=0, m=1: Solid, (Yd: 40.0 %) NMR (DMSO + TFA, 400 MHz): 2.6-3.1 (7H, m); 3.2-3.60 (2H, m); 4.15 (1H, m); 6.9-7.2 (10H, m); 7.7- 8.4(2H, m) (CHO, cis / trans isomers) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 35 / 65, Rt= 16.7 min
[0154] Id-1 (S)-2-((R)-3-(biphenyl-4-yl)-2-(N-hydroxyformamido)propanamido)propanoic acid R1= (R)-CH2Ph(4-Ph), R2= (S)-CH3, n=m=0: solid, (Yd: 21.9 %) NMR (DMSO + TFA, 400 MHz): 1.15 (3H, t); 2.5-3.2 (4H, m); 3.40-3.70 (1H, m); 4.15 (1H, t); 7.1-7.5 (9H, m); 7.7- 8.4(2H, m) (CHO, cis / trans isomers) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 4 / 6, Rt= 9.6 min
[0155] Id-2 (S)-2-((S)-3-(biphenyl-4-yl)-2-(N-hydroxyformamido)propanamido)propanoic acid R1= (S)-CH2Ph(4-Ph), R2= (S)-CH3, n=m=0:Solid, (Yd: 29.2 %) NMR (DMSO + TFA, 400 MHz): 1.0 (3H, t); 2.5-2.75 (2H, m); 3.0 (1H, m); 3.30-3.70 (2H, m); 4.05 (1H, qt); 7.1-7.55 (9H, m); 7.7- 8.4(2H, m) (CHO, cis / trans isomers) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 4 / 6, Rt= 12.6 min
[0156] Ie-1 (S)-2-benzyl-3-((R)-2-benzyl-3-(N-hydroxyformamido)propanamido)propanoic acid R1= (R)-CH2Ph, R2= (S)-CH2Ph, n=1, m=0: Solid, (Yd: 8.7 %) NMR (DMSO + TFA, 400 MHz): 2.15-2.85 (9H, m); 3.15-3.40 (2H, m); 7.0-7.4 (10H, m); 7.7-8.2 (2H, m) (CHO, cis / trans isomers) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 30 / 70, Rt= 17.6 min
[0157] Ie-2 (S)-2-benzyl-3-((S)-2-benzyl-3-(N-hydroxyformamido)propanamido)propanoic acid R1= (S)-CH2Ph, R2= (S)-CH2Ph, n=1, m=0: Solid, (Yd: 9.6 %) NMR (DMSO + TFA, 400 MHz): 2.15-2.85 (9H, m); 3.15-3.40 (2H, m); 7.05-7.35 (10H, m); 7.9-8.35 (2H, m) (CHO, cis / trans isomers) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 30 / 70, Rt= 20.0 min
[0158] Chiral synthesis of compound XIIIa-1 Step 1: Synthesis of the salt of 2-benzylacrylic acid Xa
[0159] [ka]
[0160] 2-Benzylacrylic acid Va (2 g, 12.3 mmol) is heated in 14 mL of thionyl chloride at reflux for 3 h. Excess SOCl2 is evaporated under reduced pressure. A clear yellow oil is obtained quantitatively and used for the next step. HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.05% TFA) 50 / 50, Rt= 3.77 min
[0161] Step 2: Synthesis of the adduct 2-benzylacrylic acid-(1R)-(+)-2,10-camphorsultam Xia
[0162] [ka]
[0163] (1R)-(+)-2,10-camphorsultam (19.7 g, 90.0 mmol) is solubilized in 200 mL of THF. The mixture is cooled to 0° C. and 60% NaH in oil (4.4 g, 110 mmol, 1.2 eq.) is added. In the form of a salt, the mixture is stirred at 0° C. for 30 min. The acid chloride Xa (19.98 g, 110 mmol, 1.2 eq.) in 100 mL of THF solution is added and the mixture is stirred at room temperature for 48 h. The THF is evaporated to dryness and the mixture is taken up in AcOEt. The organic phase is washed with 1N HCl, 10% NaHCO3, H2O, a saturated solution of NaCl, then dried over Na2SO4, evaporated to dryness and after recrystallization with ether, compound XIa (18.3 g, Yd: 56%) is obtained as a white solid. NMR (CDCl3, 400 MHz): 0.8-2.0 (12H, m); 2.55 (1H, q); 3.05(1H, d); 3.40 (1H, dd); 3.55 (1H, dd); 3.95 (1H, t); 5.30 (1H, s); 5.80 (1H, s); 7.10-7.40 (5H, m) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.1% TFA) 70 / 30, Rt= 13.7 min
[0164] Step 3: Synthesis of the adduct 2-benzyl-3-(benzyloxyamino)propanoic acid-(1R)-(+)-2,10-camphorsultam XIIa
[0165] [ka]
[0166] Compound XIa (1.05 g, 2.9 mmol) is solubilized in 10 mL of CH2Cl2. Benzylhydroxylamine VIa (864 mg, 7 mmol, 2.4 eq.) is added and the mixture is heated to reflux for 24 h. The mixture is diluted with CH2Cl2 and water. The organic phase is washed with 1N HCl, H2O, a saturated solution of NaCl, dried over Na2SO4 and then evaporated to dryness to give 1.45 g of a colorless oil.
[0167] After crystallization with EtOH, 790 mg of a white solid (XIIa) is obtained (Yd: 56%). NMR (CDCl3, 400 MHz): 0.8 (3H, s); 1.0 (3H, s); 1.1-1.9 (7H, m); 2.55 (1H, q); 2.95(1H, dd); 3.05(1H, dd); 3.15 (1H, t); 3.35 (3H, m); 3.60 (4H, m); 3.80 (1H, t); 4.45 (2H, s); 7.10-7.40 (10H, m) HPLC Symmetry C18, 4.6 x 250 mm, CH3CN / H2O (0.1% TFA) 60 / 40, Rt= 15.0 min
[0168] Step 4: Hydrolysis of the chiral auxiliary: Synthesis of 2-benzyl-3-(benzyloxyamino)propanoic acid XIIIa-1
[0169] [ka]
[0170] Compound XIIa (700 mg, 1.45 mmol) is solubilized in 30 mL of THF. 6 mL of 1N LiOH is added and the mixture is stirred at 55 °C for 48 h. The mixture is acidified to pH 1-2 with 1N HCl. THF is evaporated to dryness and the mixture is taken up in AcOEt. The organic phase is washed with H2O, a saturated solution of NaCl, dried over Na2SO4 and then evaporated to dryness to give 400 mg of a slightly yellow oil. The product is purified by a silica column using CH2Cl2 / MeOH 9 / 1 as elution system to give 174 mg of compound XIIIa-1 (Yd: 44.0%) as an oil that crystallizes. NMR (CDCl3, 400 MHz): 2.75 (1H, m); 2.85-3.10 (1H, q); 4.65 (2H, s); 7.1-7.4 (10H, m) HPLC Kromasil C18, 4.6 x 250 mm, CH3CN / H2O (0.1% TFA) 4 / 6 Rt= 12.3 min
[0171] Step 5: Synthesis of (2S)-benzyl 2-(2-benzyl-3-(N-(benzyloxy)formamido)propanamido)propanoic acid IIIa-1
[0172] [ka]
[0173] Acid XIIIa-1 (12 mg, 0.042 mmol) is solubilized in formic acid (1 mL) at 0° C., acetic anhydride (0.5 mL) is added at 0° C. and the mixture is stirred at 0° C. for 4 h. The mixture is poured into dichloromethane and water. The organic phase is washed with a saturated solution of NaCl, dried over Na2SO4 and evaporated to dryness to give acid IIIa-1 (13 mg, Yd: 100%) in the form of a colorless oil, which is used as such in the next step.
[0174] [ka]
[0175] The acid IIIa-1 (13 mg, 0.042 mmol) and the salt of the benzyl ester of (S)-alanine (11 mg, 0.054 mmol, 1.3 equiv.) were solubilized in 1 mL of DMF at 0° C., TBTU (12 mg, 0.052 mmol, 1.3 equiv.) and DIEA (22 μL, 0.126 mmol, 3 equiv.) were added and the mixture was stirred at room temperature for 15 min. The DMF was evaporated under reduced pressure and the mixture was taken up in AcOEt. The organic phase was washed with a 10% aqueous solution of citric acid, a saturated aqueous solution and dried over Na2SO4.
[0176] The crude mixture is purified by semi-preparative HPLC on a Kromasil C18 column 21.2×250 mm using CH3CN / H2O (0.1% TFA) 65 / 35 as the elution system to give 3.8 mg of compound IIa-1 (Yd=19.0%). NMR (DMSO + TFA, 400 MHz): 1.3 (3H, t); 2.8-3.8 (5H, m); 4.25 (1H, q); 4.65-4.85 (2H, m); 5.15 (2H, s); 7.0-7.4 (10H, m); 7.7 and 8.15 (1H, m) CHO (cis / trans isomerism); 8.45-8.65 (1H, NH, m) (cis / trans isomerism) HPLC Symmetry C18, 4.6 x 250 mm, CH3CN / H2O (0.1% TFA) 6 / 4, Rt= 11.94 (96.0% diastereomers 2R, 3S) and 11.69 min (4.0 % diastereomers 2S, 3S)
[0177] The absolute configuration of the carbon bearing the benzyl group is determined by NMR analysis according to the rules established by Fournie-Zaluski et al. in J Med Chem (1986), 29, 751-753.
[0178] Thus, the absolute configuration assigned to compound IIa-1 is (2R,3S) with an enantiomeric excess of 96% during Michael addition in the presence of a chiral auxiliary. This chiral synthesis may also be applicable to the other analogue.
[0179] Measuring restraint Different Zn-receptor enzymes, such as type 1 neprilysin (EC 3.4.24.11, NEP-1), neutral aminopeptidase (EC 3.4.11.2, APN) and LTA4H, are inhibitory and representative of this family of enzymes. 2+ The claimed inhibitors were tested against the peptidases.
[0180] The assay is carried out in 99-well plates in the presence of specific fluorogenic substrates for each enzyme.
[0181] Generally speaking, the inhibitor is pre-incubated with the enzyme at increasing concentrations for 10 min at 37°C. Then, the substrate is added and the mixture is incubated at 37°C for 30-60 min. The reaction is stopped at 4°C and the fluorescence emitted is read by reading a Berthold Twinkle LS970B plate. The inhibition curve is then plotted as a function of the inhibitor concentration using GraphPad software. Ki is then calculated according to the Cheng Prusoff equation: Ki=IC 50 It was determined from / (1+(S / Km)).
[0182] Neprilysin (NEP) assay Neprilysin, purified from rabbit kidney (Aubry M et al. (1987), Biochem Cell Biol 65, 398-404), is used at 200 ng / mL final in 50 mM Tris buffer, pH 7.4. The substrate, Dansyl-Gly-(NO2)Phe-ss-Ala (Goudreau N et al. (1994), Anal Biochem, 219, 87-95) (Km=37 μM), is dissolved in ethanol and used at 20 μM final. Increasing concentrations of inhibitor (10 -10 From 10 -3 M) is pre-incubated for 15 min at 37° C. Substrate is then added and incubation is continued for up to 60 min. The reaction is stopped by placing the plate on ice for 10 min. Reading of the emitted fluorescence is performed in a fluorometer at λex=355 nm, λem=535 nm.
[0183] Neutral aminopeptidase (APN) assay Measurement of inhibition of aminopeptidase N (APN) is carried out using the substrate L-Ala↓ss-NA (50 μM, Sigma Aldrich). Inhibitory potency is determined using recombinant human enzyme (rh) (50 ng / mL; R&D Systems). Increasing concentrations of inhibitor (10 -10 From 10 -3M) is pre-incubated for 30 min at 37° C. Substrate is then added and incubation is continued for 30 min at 37° C. The reaction is stopped by placing the plate on ice for 10 min. The emitted fluorescence is read in a fluorometer at λex=340 nm, λem=405 nm.
[0184] LTA4 hydrolase assay To determine the Ki values of different inhibitors with respect to LTA4H, 0.6 μg / mL of the recombinant enzyme was incubated at 37°C for 30 min in 50 mM Tris-HCl buffer, pH 7.4, 100 mM NaCl, and increasing concentrations (final concentrations of 10 -10 M to 10 -4 The mixture was preincubated with 10 mM glycerol (L)-Ala-β-naphthylamide (1 mM) in a final volume of 100 μL and incubated for 15 min at 37 °C. The fluorescence value was measured in a Berthold Twinkle LB 970 (λex=340 nm, λem=405 nm, lamp energy 10000). Samples containing 0% hydrolysis were obtained by adding the substrate to the buffer, and samples with 100% relative activity were prepared without inhibitor. The cleavage rate was evaluated and compared to the 100% relative activity, resulting in an IC 50 The Ki values of inhibitors (average of at least three independent duplicate assays) were calculated using the formula Ki=IC50 / (1+[S] / Km).
[0185] Results: Inhibitory effects of NEP, APN, and LTA4H H-CO-N(OH)-CH2-CH(R1)-CO-NH-(CH2) n CH(R2)(CH2) m -CO-R3(1)
[0186] [Table 1]
[0187] Pharmacology Testing FIG. 1 shows that the intravenous combination of THC and compound Ib-1 at doses inactive in this test induces a significant synergistic analgesic effect in the hot plate test in male OF1 mice 10 min after injection.
Claims
1. The following chemical formula (I): H-CO-N(OH)-CH 2 -CH(R 1 )-CO-NH-(CH 2 ) n -CH(R 2 )-(CH 2 ) m -CO-R 3 (AND) [In the formula, R 1 Below: - aryl, unsubstituted or substituted with halogen, phenyl, benzyl, OR 4 Group (R 4 is selected from hydrogen, and a linear or branched alkyl group containing 1 to 4 carbon atoms, and a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, substituted with one or more groups selected from aryl, which is substituted with one or more groups selected from hydrogen, and a linear or branched alkyl group containing 1 to 4 carbon atoms, and combinations thereof; represents R 2 Below: - unsubstituted or aryl, unsubstituted or halogen, OR 5 Group (R 5 is selected from hydrogen, a linear or branched alkyl group containing 1 to 4 carbon atoms, and a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, substituted with one or more groups selected from aryl, which is substituted with one or more groups selected from hydrogen, a linear or branched alkyl group containing 1 to 4 carbon atoms, and combinations thereof; represents R 3 represents OH, m and n are, independently of one another, integers selected from 0 and 1; R 1 The carbon atom having the formula (R) has the absolute configuration (R) and 2 The carbon atom having the formula: has absolute configuration (S). and pharma- ceutically acceptable salts and / or solvates thereof.
2. R 1 2. The compound according to claim 1, wherein R represents a linear or branched alkyl group containing from 1 to 6 carbon atoms, which is itself unsubstituted or substituted with a phenyl group which is substituted with a phenyl group.
3. R 2 3. The compound according to claim 1 or 2, wherein represents an unsubstituted or aryl-substituted linear or branched alkyl group containing from 1 to 6 carbon atoms.
4. - R 1 = (R)-CH 2 Ph; R 2 = (S)-CH 3 ; R 3 = OH; n=m=0; - R 1 = (R)-CH 2 Ph; R 2 = (S)-CH 2 Ph; R 3 = OH; n=m=0; - R 1 = (R)-CH 2 Ph; R 2 = (S)-CH 2 Ph; R 3 = OH; n=0; m=1; - R 1 = (R)-CH 2 Ph-4-Ph; R 2 = (S)-CH 3 ; R 3 = OH; n=m=0; - R 1 = (R)-CH 2 Ph; R 2 = (S)-CH 2 Ph; R 3 = OH; n=1; m=0 4. The compound according to claim 1, wherein
5. 5. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 4 and at least one pharma- ceutically acceptable excipient.
6. The pharmaceutical composition of claim 5, further comprising at least one other active ingredient.
7. The pharmaceutical composition described in claim 6, wherein the other active ingredients further include an analgesic selected from morphine and its derivatives, inhibitors of endocannabinoids and their metabolism, GABA derivatives, and duloxetine or channel inhibitors.
8. 8. A pharmaceutical composition according to any one of claims 5 to 7 for use as an analgesic, anxiolytic, antidepressant or anti-inflammatory agent.
9. 8. A pharmaceutical composition according to any one of claims 5 to 7 for the treatment of acute or chronic pain.
10. The pharmaceutical composition of claim 9, wherein the acute or chronic pain is selected from the group consisting of postoperative pain, cancer pain, traumatic pain, headache, migraine, visceral pain, neurogenic pain, neuropathic pain, neuroinflammatory pain, nociceptive pain, or general pain.
11. The following chemical formula (II): H-CO-N(OR)-CH 2 -CH(R 1 )-CO-NH-(CH 2 ) n -CH(R 2 )-(CH 2 ) m -CO-R 3 (II) [In the formula, R is: - a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, which is unsubstituted or substituted by one or more aryl groups, which are aryl groups, which are unsubstituted or substituted by one or more groups selected from aryl or linear or branched alkyl groups containing 1 to 4 carbons, or -Si(R 10 ) 3 The group R 10 is a linear or branched alkyl group containing 1 to 4 carbon atoms; Si(R 10 ) 3 base represents R 1 Below: aryl, unsubstituted or halogen, phenyl, benzyl, OR 4 Group (R 4 is selected from hydrogen and a linear or branched alkyl group containing 1 to 4 carbon atoms), and a linear or branched hydrocarbon group containing 1 to 6 carbon atoms substituted with one or more groups selected from aryl, which is substituted with one or more groups selected from hydrogen and a linear or branched alkyl group containing 1 to 4 carbon atoms, and combinations thereof. represents R 2 is the following: - unsubstituted or aryl, unsubstituted or halogen, OR 5 Group (R 5 is selected from hydrogen, a linear or branched alkyl group containing 1 to 4 carbon atoms, and a linear or branched hydrocarbon group containing 1 to 6 carbon atoms, substituted with one or more groups selected from aryl, which is substituted with one or more groups selected from hydrogen, a linear or branched alkyl group containing 1 to 4 carbon atoms, and combinations thereof; represents R 3 represents OH, m and n are, independently of one another, integers selected from 0 and 1; R 1 The carbon atom having the formula (R) has the absolute configuration (R) and 2 The carbon atom having the formula: and pharma- ceutically acceptable salts and / or solvates thereof.
Citation Information
Patent Citations
Derivatives of amino acids and their therapeutic use.
FR2518088A1
Amino-acid derivatives, their preparation and pharmaceutical compositions containing them.
FR2605004A1
Novel amino acid derivatives, method for preparing them, and their therapeutical applications
FR2651229A1
new DERIVATIVES OF (ALPHA-AMINOPHOSPHINO)PEPTIDES, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM
FR2755135A1
Alpha amino phosphino peptide derivatives having morphine-like analgesic properties
FR2777780A1
